To study clinical course, outcomes and risk factors for ICANS in older patients with large B cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel)
Latest Information Update: 28 Jul 2021
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 28 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology